20
Participants
Start Date
March 17, 2022
Primary Completion Date
November 19, 2023
Study Completion Date
February 8, 2024
lacutamab
Patients will receive a fixed dose of 750mg as 1-hour IV infusion
Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care, New York
Allegheny Health, Pittsburgh
University of Maryland, Baltimore
Medical University of South Carolina - Health Hollings Cancer Center, Charleston
Chungnam National University Hospital, Daejeon
University of Alabama at Birmingham- O'Neal Comprehensive Cancer Center, Birmingham
Indiana University School of Medicine, Indianapolis
Goshen Health- Goshen Hospital, Goshen
University of Iowa, Iowa City
The University of Texas MD Anderson Cancer Center, Houston
University of California at Irvine - Chao Family Comprehensive Cancer Center, Orange
Inje University Busan Paik Hospital, Busan
Seoul National University Bundang Hospital, Gyeonggi-do
Gachon University Gil Medical Center, Incheon
Asan Medical Center, Seoul
Korea University Anam Hospital, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital Yonsei University Health System, Seoul
The Catholic University of Korea, Yeouido St. Mary's Hospital, Seoul
Lead Sponsor
Innate Pharma
INDUSTRY